Boehringer Ingelheim has made a significant bet that the kind of contract services it offers elsewhere will be a big draw in China, opening a $77 million contract biologics plant there last year. Now, it is expanding it.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,